Relmada Secures $160M in Oversubscribed Private Placement, Reports Strong 12-Month Phase 2 Bladder Cancer Data

summarizeSummary

Relmada Therapeutics announced an oversubscribed private placement raising $160.0 million at a discount, alongside positive 12-month Phase 2 data for its NDV-01 bladder cancer treatment, supporting its advancement to Phase 3.

check_boxKey Events

• Oversubscribed Private Placement Finalized

  The company finalized an oversubscribed private placement, raising approximately $160.0 million in gross proceeds. This substantial capital raise, announced earlier today, involved the sale of 29,474,569 shares of common stock at $4.75 per share and pre-funded warrants to purchase 4,210,527 shares at $4.749 per pre-funded warrant (exercise price $0.001). The offering price of $4.75 is at a discount to the current stock price of $5.94.

• Positive 12-Month Phase 2 Data for NDV-01

  Relmada reported strong 12-month interim data from its Phase 2 trial of NDV-01 in high-risk non-muscle invasive bladder cancer (NMIBC). The trial showed a 76% complete response (CR) rate at 12 months in the overall population and an 80% CR rate in the Bacillus Calmette-Guérin (BCG)-unresponsive population, with a favorable safety profile.

• Advancement to Phase 3 Registrational Program

  The positive Phase 2 results support the advancement of NDV-01 into a Phase 3 RESCUE registrational program, which will include two distinct pathways: second-line BCG-unresponsive NMIBC and adjuvant intermediate-risk NMIBC. Key milestones include IND clearance and Phase 3 initiation in mid-2026.

• Funding for Research and Development

  The net proceeds from the private placement will be used for working capital and general corporate purposes, specifically including the advancement of research and development for its product candidates, providing crucial funding for the upcoming Phase 3 program for NDV-01.

auto_awesomeAnalysis

This 8-K filing details two highly significant, synergistic events for Relmada Therapeutics. The company has successfully secured approximately $160.0 million through an oversubscribed private placement, which is a substantial capital infusion representing nearly half of its current market capitalization. While the offering price of $4.75 per share and pre-funded warrant is at a discount to the current market price of $5.94, the oversubscribed nature indicates strong institutional investor confidence, likely driven by the concurrently announced positive clinical data. The proceeds are earmarked for working capital and general corporate purposes, critically including the advancement of research and development for its product candidates.

Simultaneously, the company reported compelling 12-month interim data from its Phase 2 trial of NDV-01 in high-risk non-muscle invasive bladder cancer (NMIBC). The drug demonstrated a durable 76% complete response rate at 12 months in the overall population, and an even higher 80% in the difficult-to-treat BCG-unresponsive population, coupled with a favorable safety profile. These strong results support the planned advancement of NDV-01 into a Phase 3 registrational program with two distinct pathways. The successful financing provides the necessary runway to fund these critical development milestones, significantly de-risking the company's pipeline and providing a clear path forward for a potentially transformative therapy.